Kimberly-Clark shares slipped 0.3% in premarket trading on Tuesday after Monday's sharp fall tied to its $48.7 billion acquisition of Kenvue. Despite the drop, sentiment turned extremely bullish, with analysts calling the deal transformative. The move comes amid controversy over Tylenol safety claims raised by the US administration.